Introduction Malignant pleural effusion (MPE) affects up to 15% of patients with cancer, and its incidence and prevalence are increasing. 1 - 4 Most cases are symptomatic; the most common symptoms are ...

DelveInsight's“ Malignant Pleural Effusion Pipeline Insight” report provides comprehensive global coverage of pipeline therapies for Malignant Pleural Effusion across various stages of clinical ...

A phase I/II, open label trial of Lewis Y specific monoclonal antibody IGN311 to evaluate safety and efficacy in patients with malignant effusion This is an ASCO Meeting Abstract from the 2006 ASCO ...

Researchers at Wake Forest School of Medicine have discovered that a nanoparticle therapeutic enhances cancer immunotherapy and is a possible new approach in treating malignant pleural effusion (MPE).

IT is the unfortunate lot of some patients dying of metastatic cancer of the breast, lung, cervix and so forth to be plagued by severe dyspnea due to recurrent malignant pleural effusions. Many of ...

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced that results from the STELLAR trial were published in The Lancet Oncology. The STELLAR trial was a prospective, single-arm ...

Please provide your email address to receive an email when new articles are posted on . The average health care cost per patient in the indwelling pleural catheter (IPC) group was $40,179 vs. $46,640 ...

(MENAFN- GetNews) The Key Malignant Pleural Effusion Companies in the market include - Genelux Corporation, RS Oncology, Canderl Therapeutics, Abnoba Korea, Jiangsu Simcere Pharmaceutical, Novartis, ...

Lung cancer patients are particularly susceptible to malignant pleural effusion, when fluid collects in the space between the lungs and the chest wall. Researchers have discovered a novel mechanism ...